Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus Ipilimumab in advanced melanoma
NCT02599402Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2015
- Primary completion
- Feb 2020
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 3 trial of nivolumab, ipilimumab in melanoma, sponsored by Bristol Myers Squibb. Started Dec 2015; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02599402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02599402.